3-O-Methyl L-DOPA monohydrate is a methylated derivative of L-DOPA (Levodopa), a key therapeutic agent for Parkinson's disease. It is a white to off-white crystalline powder with the molecular formula C10H13NO4·H2O. This compound is primarily known as the major active metabolite of L-DOPA, formed in the body via the action of catechol-O-methyltransferase (COMT). Its primary application is in the field of neuroscience and pharmacology. As a metabolite, it serves as a crucial reference standard in bioanalytical studies for monitoring L-DOPA pharmacokinetics and metabolism in patients. It is used in the development and validation of analytical methods (e.g., HPLC, LC-MS) for quantifying L-DOPA and its metabolites in biological fluids, which is essential for drug development and therapeutic drug monitoring. While it possesses some dopaminergic activity, its therapeutic potency is significantly lower than L-DOPA itself. The compound is also of research interest in studying the metabolic pathways of catecholamines and the role of COMT inhibition. As a high-purity chemical reference material, it is vital for ensuring the accuracy and reliability of clinical and preclinical data related to Parkinson's disease treatment.